David Harrell

Chief Executive Officer

Therapeutic Areas

Drug	Indication	Phase
Proof-of-Concept Project	Platform Validation	Preclinical
Oncology Program	Cancer Therapy	Research
Neurodegenerative Program	Neurodegenerative Disorder	Research
Cardiovascular Program	Cardiovascular Disease	Research